

Title (en)

HYALURONIC ACID AS DNA CARRIER FOR GENE THERAPY AND VEGF ANTISENSE DNA TO TREAT ABNORMAL RETINAL VASCULARIZATION

Title (de)

HYALURONSÄURE ALS DNA TRÄGER FÜR DIE GENTHERAPIE SOWIE VEGF ANTISENSE-DNA ZUR BEHANDLUNG ABNORMALER NETZHAUTVASKULARISIERUNG

Title (fr)

ACIDE HYALURONIQUE UTILISE COMME PORTEUR D'ADN POUR UNE THERAPIE GENIQUE ET ADN ANTI-SENS DU FACTEUR DE CROISSANCE DE L'ENDOTHELIUM VASCULAIRE POUR LE TRAITEMENT D'UNE VASCULARISATION ANORMALE DE LA RETINE

Publication

EP 0859636 A4 20020502 (EN)

Application

EP 96934189 A 19961022

Priority

- AU 9600664 W 19961022
- AU PN616195 A 19951023
- AU PN904796 A 19960401

Abstract (en)

[origin: WO9715330A1] The invention provides methods and compositions for gene therapy, including antisense therapy. In one embodiment, the compositions comprise hyaluronic acid to promote uptake of nucleic acid by the target cells. The invention is illustrated with reference to treatment of retinal diseases caused by neovascularisation.

IPC 1-7

C12N 15/11; **A61K 48/00**; **A61K 47/48**; **C07K 14/52**; **A61K 47/36**

IPC 8 full level

C12N 15/00 (2006.01); **A61K 9/00** (2006.01); **A61K 31/00** (2006.01); **A61K 31/70** (2006.01); **A61K 31/7088** (2006.01); **A61K 31/711** (2006.01); **A61K 35/76** (2006.01); **A61K 38/22** (2006.01); **A61K 47/36** (2006.01); **A61K 47/48** (2006.01); **A61K 48/00** (2006.01); **A61P 27/00** (2006.01); **A61P 27/02** (2006.01); **C07K 14/52** (2006.01); **C12N 15/113** (2010.01); **A61K 38/00** (2006.01)

CPC (source: EP KR)

A61K 9/0014 (2013.01 - EP); **A61K 9/0019** (2013.01 - EP); **A61K 47/36** (2013.01 - EP KR); **A61K 47/61** (2017.07 - EP); **A61K 48/00** (2013.01 - EP KR); **A61P 27/00** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **C07K 14/52** (2013.01 - EP); **C12N 15/1136** (2013.01 - EP); **C12N 15/1137** (2013.01 - EP); **C12Y 304/22027** (2013.01 - EP); **C12Y 304/23005** (2013.01 - EP); **A61K 38/00** (2013.01 - EP); **C12N 2310/111** (2013.01 - EP); **C12N 2310/315** (2013.01 - EP); **C12N 2799/022** (2013.01 - EP); **C12N 2799/025** (2013.01 - EP)

Citation (search report)

- [Y] SMITH L E H ET AL: "INHIBITION OF PROLIFERATIVE RETINOPATHY USING ANTISENSE PHOSPHOROTHIOATE OLIGONUCLEOTIDES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF/VPF)", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 36, no. 4, 15 March 1995 (1995-03-15), pages S871, abstract no. 3992, XP002008713, ISSN: 0146-0404
- [YP] ROBINSON GREGORY S ET AL: "Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 10, 1996, pages 4851 - 4856, XP002137716, ISSN: 0027-8424
- [Y] MUMPER R J ET AL: "NOVEL POLYMERIC CONDENSING CARRIERS FOR GENE DELIVERY", PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE BIOACTIVE MATERIALS, XX, XX, vol. 22, 30 July 1995 (1995-07-30), pages 178, XP002048876, ISSN: 1022-0178
- [Y] DATABASE CANCERLIT [online] NATIONAL CANCER INSTITUTE, BETHESDA, MD, US; MITCHELL SD ET AL: "Antisense RNA to the cell adhesion gene CD44 in melanoma cells (Meeting abstract).", XP002177966, retrieved from DIALOG accession no. 01061823 Database accession no. 94699907 & J PATHOL; 170, 1993, (SUPPL), ISSN: 0022-3417
- [T] ELLIS LM ET AL: "Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation.", SURGERY, NOV 1996, VOL. 120, NO. 5, PAGE(S) 871-878, XP001027824, ISSN: 0039-6060
- See references of WO 9715330A1

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9715330 A1 19970501; CA 2235685 A1 19970501; CN 1209068 A 19990224; EP 0859636 A1 19980826; EP 0859636 A4 20020502; JP 2000507915 A 20000627; KR 19990066967 A 19990816; MY 134778 A 20071231; NZ 320006 A 20011221

DOCDB simple family (application)

AU 9600664 W 19961022; CA 2235685 A 19961022; CN 96199290 A 19961022; EP 96934189 A 19961022; JP 51613797 A 19961022; KR 19980702900 A 19980422; MY PI9604371 A 19961022; NZ 32000696 A 19961022